| Literature DB >> 34246969 |
Relja Suručić1, Maja Travar2, Miroslav Petković3, Biljana Tubić4, Miloš P Stojiljković5, Milkica Grabež6, Katarina Šavikin7, Gordana Zdunić8, Ranko Škrbić9.
Abstract
The novel coronavirus disease (Covid-19) has become a major health threat globally. The interaction of SARS-CoV-2 spike (S) glycoprotein receptor-binding domain (RBD) with ACE2 receptor on host cells was recognized as the first step of virus infection and therefore as one of the primary targets for novel therapeutics. Pomegranate extracts are rich sources of bioactive polyphenols that were already recognized for their beneficial health effects. In this study, both in silico and in vitro methods were employed for evaluation of pomegranate peel extract (PoPEx), their major polyphenols, as well as their major metabolite urolithin A, to attenuate the contact of S-glycoprotein RBD and ACE2. Our results showed that PoPEx, punicalin, punicalagin and urolithin A exerted significant potential to block the S-glycoprotein-ACE2 contact. These in vitro results strongly confirm the in silico predictions and provide a valuable insight in the potential of pomegranate polyphenols for application in SARS-CoV-2 infection.Entities:
Keywords: ACE2; Pomegranate; Punicalagin; Punicalin; SARS-CoV-2; Spike glycoprotein; Urolithin A
Year: 2021 PMID: 34246969 PMCID: PMC8256661 DOI: 10.1016/j.bioorg.2021.105145
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275
The quantity of the most abundant pomegranate peel extract (PoPEx) polyphenols and their retention times determined by using HPLC method.
| 4.9 | Gallic acid | 7.74 ± 0.29 |
| 5.8 | Punicalin | 31.31 ± 0.71 |
| 8.6 | α-Punicalagin | 26.02 ± 6.77 |
| 10.9 | β-Punicalagin | 45.57 ± 4.62 |
| 25.2 | Ellagic acid | 22.82 ± 0.22 |
milligrams per gram of dry weight.
Fig. 1The HPLC chromatogram of pomegranate peel extract (PoPEx) major constituents.
Molecular docking study results for the PoPEx most abundant compounds and their metabolite urolithin A.
| Ellagic acid | −7.56 | Asn 343, Ser 373, Asn 437, Asn 440, Arg 509 |
| Gallic acid | −6.29 | Asp 467, Ser 469, Glu 471 |
| Punicalin | −9.25 | Asp 428, Pro 463, Phe 515, Glu 516, Leu 517 |
| Punicalagin | −7.79 | Glu 340, Ala 348, Ala 352, Ser 399, Asn 450 |
| Urolithin A | −6.86 | Asn 343, Asp 364, Val 362 |
| Umifenovir (positive control) | −5.97 | Thr 430 |
Fig. 2Molecular docking ligand S-glycoprotein interactions with: a) Ellagic acid, b) Gallic acid, c) Punicalagin, d) Punicalin, e) Umifenovir and f) Urolithin A.
Fig. 3The MD simulation results of a) RMSD, b) Radius of gyration (Rg) and c) Fraction of Native Contacts (Qx) of the most stable complexes ligand-receptor complexes from the docking studies.
Fig. 4The SARS-CoV-2 inhibition activity in vitro results.
Fig. 5The IC50 equations and concentration-inhibition response of PoPEx and punicalin against S-glycoprotein-ACE2 interaction.